A retrospective comparison of the efficacy and safety in kidney transplant recipients with basiliximab and anti-thymocyte globulin

Chinese Medical Journal

Volumn 125, Issue 6, 2012, Pages 1135-1140

  Wang, Wei ^a   Yin, Hang ^a   Li, Xiao Bei ^a   Hu, Xiao Peng ^a   Yang, Xiao Yong ^a   Liu, Hang ^a   Ren, Liang ^a   Wang, Yong ^a   Zhang, Xiao Dong ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Anti thymocyte globulin; Basiliximab; Inducing treatment; Kidney transplantation

Indexed keywords

BASILIXIMAB; CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ACUTE HEART FAILURE; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DELAYED GRAFT FUNCTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; GRANULOCYTOPENIA; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; SCHOOL CHILD; THROMBOCYTOPENIA;

ADULT; ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES;

EID: 84862258875     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.06.030     Document Type: Article

References (32)

1. Hariharan S, Johnson CP, Bresnahan B, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in United States, 1988 to 1996. N Engl J Med 2000; 342: 605-612.
2. Lawen JG, Davies EA, Mourad G, Oppenheimer F, Molina MG, Rostaing L, et al. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. Transplantation 2003; 75: 37-43.
3. Sheashaa HA, Bakr MA, Ismail AM, Mahmoud KM, Sobh MA, Ghoneim MA. Basiliximab induction therapy for live donor kidney transplantation: a long-term follow-up of prospective randomized controlled study. Clin Exp Nephrol 2008; 3: 376-381.
4. Lee BM, Oh CK, Jin SH, Kim JH, Kim SJ, Kim H, et al. Effect of basiliximab on renal allograft rejection within 1 year after transplantation. Transplant Proc 2006; 38: 2025-2028.
5. Duzova A, Buyan N, Bakkaloglu M, Dalgic A, Soylemezoglu O, Besbas N, et al. Triple immunosuppression with or without basiliximab in pediatric renal transplantation: acute rejection rates at one year. Transplant Proc 2003; 35: 2878-2880.
6. Nashan B. Antibody induction therapy in renal transplant patients receiving calcineurin-inhibitor immunosuppressive regimens: a comparative review. BioDrugs 2005; 19: 39-46.
7. Brennan DC, Daller JA, Lake KD Cibrik D, Del Castillo D; Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006; 355: 1967-1977.
8. Meier-Kriesche HU, Arndorfer JA, Kaplan B. Association of antibody induction with short- and long-term cause specific mortality in renal transplant recipients. J Am Soc Nephrol 2002; 13: 769-772.
9. Zand MS, Vo T, Huggins J, Liesveld J, Pellegrin T, Bozorgzadeh A, et al. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 2005; 79: 1507-1515.
10. Grenda R, Watson A, Vondrak K, Webb NJ, Beattie J, Fitzpatrick M, et al. A prospective, randomized, multicenter trial of tacrolimus based therapy with or without basiliximab in pediatric renal transplantation. Am J Transplant 2006; 6: 1666-1772.
11. Ojogho O, Sahney S, Cutler D, Baron PW, Abdelhalim FM, James S, et al. Mycophenolate mofetil in pediatric renal transplantation: non-induction vs. induction with basiliximab. Pediatr Transplant 2005; 9: 80-83.
12. Kyllönen LE, Eklund BH, Pesonen EJ, Salmela KT. Single bolus antithymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporin triple immunosuppression: efficacy and safety. Transplantation 2007; 84: 75-82.
13. Yang SL, Wang D, Wu WZ, Lin WH, Xu TZ, Cai JQ, et al. Comparison of single bolus ATG and basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen. Transpl Immunol 2008; 18: 281-285.
14. Heifets M, Saeed MI, Parikh MH, Sierka D, Kumar MS. Induction immunosuppression in kidney transplant recipients older than 60 years of age. Safety and efficacy of ATGAM, OKT3 and Simulect. Drugs Aging 2004; 21: 747-756.
15. Clark G, Walsh G, Deshpande P, Koffman G Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation. Nephrol Dial Transplant 2002; 17: 1304-1309.
16. Favi E, Gargiulo A, Spagnoletti G, Salerno MP, Silvestrini N, Valente I, et al. Induction with basiliximab plus thymoglobulin is effective and safe in old-for-old renal transplantation: six-month results of a prospective clinical study. Transplant Proc 2010; 42: 1114-1117.
17. Al Najjar A, Etienne I, Le Pogamp P, Bridoux F, Le Meur Y, Toupance O, et al. Long-term results of monoclonal anti-IL2-receptor antibody versus polyclonal antilymphocyte antibodies as induction therapy in renal transplantation. Transplant Proc 2006; 38: 2298-2299.
18. Chen LZ, Chen GD, Wang CX, Fei JG, Qiu J, Deng SX, et al. Outcome of cadaveric kidney transplantation: analysis of 1806 cases. Chin J Urol (Chin) 2006; 27: 166-170.
19. Wang W, Li XB, Yin H, Yang XY, Liu H, Ren L, et al. Factors affecting the long-term renal allograft survival. Chin Med J 2011; 12: 1181-1184.
20. Gonçalves LF, Ribeiro AR, Berdichevski R, Joelsons G, Proença MC, Manfro RC. Basiliximab improves graft survival in renal transplant recipients with delayed graft function. Transplant Proc 2007; 39: 437-438.
21. Sandrini S. Use of IL-2 receptor antagonists to reduce delayed graft function following renal transplantation: a review. Clin Transplant 2005; 19: 705-710.
22. Mehra MR, Zucker MJ, Wagoner L, Michler R, Boehmer J, Kovarik J, et al. A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation. J Heart Lung Transplant 2005; 24: 1297-1304.
23. Lebranchu Y, Bridoux F, Büchler M, Le Meur Y, Etienne I, Toupance O, et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002; 2: 48-56.
24. Mourad G, Rostaing L, Legendre C, Garrigue V, Thervet E, Durand D. Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation 2004; 78: 584-590.
25. Oner-Eyüboǧlu F, Karacan O, Akçay S, Arslan H, Demirhan B, Haberal M. Invasive pulmonary fungal infections in solid-organ transplantation recipients: a four-year review. Transplant Proc 2003; 35: 2689-2691.
26. Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW. Association of the type of induction immnosuppression with post transplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003; 76: 1289-1293.
27. Jindal RM, Das NP, Neff RT, Hurst FP, Falta EM, Elster EA, et al. Outcomes in African-Americans vs. Caucasians using thymoglobulin or interleukin-2 receptor inhibitor induction: analysis of USRDS database. Am J Nephrol 2009; 29: 501-508.
28. Al Najjar A, Etienne I, Le Pogamp P, Bridoux F, Le Meur Y, Toupance O, et al. Long-term results of monoclonal anti-IL2-receptor antibody versus polyclonal antilymphocyte antibodies as induction therapy in renal transplantation. Transplant Proc 2006; 38: 2298-2299.
29. high regulatory T cells in kidney transplantation. Transpl Immunol 2008; 19: 69-73.
30. Wang Z, Shi BY, Qian YY, Cai M, Wang Q. Short-term anti-CD25 monoclonal antibody administration down-regulated CD25 expression without eliminating the neogenetic functional regulatory T cells in kidney transplantation. Clin Exp Immunol 2009; 155: 496-503.
31. Wang W, Li XB, Yang XY, Zhang XD. Forkhead box protein 3 mRNA expression in the peripheral blood of kidney-transplant recipients with acute rejection. Chin Med J 2011; 124: 1775-1778.
32. + cells in renal allografts during acute rejection. Am J Transplant 2007; 7: 914-922.